• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Werewolf Therapeutics Inc.

    5/8/25 4:06:12 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOWL alert in real time by email
    S-8 1 d905188ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 8, 2025

    Registration No. 333-__________

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Werewolf Therapeutics, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   82-3523180
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification No.)

    200 Talcott Ave, 2nd Floor

    Watertown, MA

      02472
    (Address of Principal Executive Offices)   (Zip Code)

    Inducement Stock Option Award

    (Full Title of the Plan)

    Daniel J. Hicklin, Ph.D.

    President and Chief Executive Officer

    Werewolf Therapeutics, Inc.

    200 Talcott Ave, 2nd Floor

    Watertown, MA 02472

    (Name and Address of Agent for Service)

    (617) 952-0555

    (Telephone Number, Including Area Code, of Agent for Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     
     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The information required by Item 1 is included in documents sent or given to the participant in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

    Item 2. Registrant Information and Employee Plan Annual Information.

    The written statement required by Item 2 is included in documents sent or given to the participant in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

    (a) the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 11, 2025, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the registrant’s definitive proxy statement for the 2025 Annual Meeting of Stockholders;

    (b) the registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, as filed with the Commission on May 8, 2025;

    (c) the registrant’s Current Report on Form 8-K as filed with the Commission on February  24, 2025; and

    (d) the description of the registrant’s securities contained in the Registration Statement on Form 8-A as filed with the Commission on April  27, 2021, as the description therein has been updated and superseded by the description of the registrant’s securities contained in Exhibit 4.3 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the Commission on March 24, 2022, and including any amendments and reports filed for the purpose of updating such description.

    All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4. Description of Securities.

    Not applicable.


    Item 5. Interests of Named Experts and Counsel.

    Wilmer Cutler Pickering Hale & Dorr LLP has opined as to the legality of the securities being offered by this registration statement.

    Item 6. Indemnification of Directors and Officers.

    Section 102 of the General Corporation Law of the State of Delaware (the “DGCL”) permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The registrant’s restated certificate of incorporation that will be effective upon the closing of its initial public offering of common stock provides that no director shall be personally liable to the registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.

    The registrant’s restated certificate of incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the registrant), by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the request of the registrant as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

    The registrant’s restated certificate of incorporation also provides that the registrant will indemnify any Indemnitee who was or is a party or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the registrant to procure a judgment in the registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the request of the registrant as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless and only to the extent that the Court of Chancery of Delaware or the


    court in which such action or suit was brought determines that, despite such adjudication but in view of all of the circumstances, he or she is fairly and reasonably entitled to indemnification of such expenses (including attorney’s fees). Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. In addition, the registrant has entered into indemnification agreements with all of the registrant’s directors and executive officers. In general, these agreements provide that the registrant will indemnify the directors or executive officers to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of the registrant or in connection with his or her service at the request of the registrant for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director.

    The registrant maintains a general liability insurance policy that covers certain liabilities of the registrant’s directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

    Item 9. Undertakings.

    1. The undersigned registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

    Number

      

    Description

     4.1    Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 5, 2021).
     4.2    Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 27, 2023).
     5.1*    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant.
    23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm.
    23.2*    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).
    24.1*    Power of attorney (included on the signature pages of this registration statement).
    99.1*    Form of Inducement Stock Option Agreement.
    107*    Calculation of Filing Fee Tables.

     

    *

    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts on this 8th day of May, 2025.

     

    WEREWOLF THERAPEUTICS, INC.
    By:   /s/ Daniel J. Hicklin

     

      Daniel J. Hicklin, Ph.D.

     

      President and Chief Executive Officer


    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Werewolf Therapeutics, Inc., hereby severally constitute and appoint Daniel J. Hicklin, Ph.D. and Timothy W. Trost, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Werewolf Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Daniel J. Hicklin    President, Chief Executive Officer and Director   May 8, 2025
    Daniel J. Hicklin, Ph.D.    (Principal Executive Officer)  

     

    /s/ Timothy W. Trost    Chief Financial Officer and Treasurer   May 8, 2025
    Timothy W. Trost    (Principal Financial and Accounting Officer)  

     

    /s/ Luke Evnin    Chairman of the Board of Directors   May 8, 2025
    Luke Evnin, Ph.D.   

     

     

     

    /s/ Michael B. Atkins    Director   May 8, 2025
    Michael B. Atkins, M.D.   

     

     

     

    /s/ Meeta Chatterjee    Director   May 8, 2025
    Meeta Chatterjee, Ph.D.   

     

     

     

    /s/ Derek DiRocco    Director   May 8, 2025
    Derek DiRocco, Ph.D.   

     

     

     

    /s/ Alon Lazarus    Director   May 8, 2025
    Alon Lazarus, Ph.D.   

     

     

     

    /s/ Briggs W. Morrison    Director   May 8, 2025
    Briggs W. Morrison, M.D.   

     

     

     

    /s/ Michael Sherman    Director   May 8, 2025
    Michael Sherman   

     

     

     

    /s/ Anil K. Singhal    Director   May 8, 2025
    Anil K. Singhal   

     

     

     

    Get the next $HOWL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOWL

    DatePrice TargetRatingAnalyst
    4/3/2024$12.00Mkt Outperform
    JMP Securities
    8/24/2023$9.00Outperform
    Wedbush
    6/6/2023$11.00 → $12.00Buy
    Jefferies
    11/19/2021$29.00 → $28.00Outperform
    SVB Leerink
    9/10/2021$26.00Buy
    BofA Securities
    More analyst ratings

    $HOWL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

      WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025. A live webcast link for the presentation will be available at https:

      5/29/25 8:00:00 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

      There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell carcinoma SCOTTSDALE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with a new targeted immune-therapy in a clinical trial at HonorHealth Research Institute. Wayne Futch, 73, of Phoenix, developed a type

      5/20/25 4:01:00 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

      WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Summit taking place May 15-16 in Boston, Massachusetts. The presentation will highlight how data from patients treated with IL-2 and IL-12 INDUKINE molecules in first-in-human clinical trials have succ

      5/13/25 8:00:00 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $487,188 worth of shares (536,426 units at $0.91) (SEC Form 4)

      4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

      5/14/25 6:08:19 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Werewolf Therapeutics Inc.

      EFFECT - Werewolf Therapeutics, Inc. (0001785530) (Filer)

      5/16/25 12:15:25 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Werewolf Therapeutics Inc.

      8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)

      5/15/25 5:00:10 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Werewolf Therapeutics Inc.

      SCHEDULE 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

      5/14/25 6:09:19 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    Leadership Updates

    Live Leadership Updates

    See more
    • Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

      WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. "Steve brings deep experience in strategic transactions to Werewolf at this critical tim

      4/17/25 8:00:00 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

      WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company advances its novel INDUKINE molecules through clinical development," said Dr. Singhal. "Werewolf is demonstrating the power of the PREDATORTM protein engineering p

      2/24/25 7:30:00 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

      WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. "Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy. I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules," sai

      1/4/24 4:05:00 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Werewolf Therapeutics with a new price target

      JMP Securities initiated coverage of Werewolf Therapeutics with a rating of Mkt Outperform and set a new price target of $12.00

      4/3/24 7:44:47 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Werewolf Therapeutics with a new price target

      Wedbush initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $9.00

      8/24/23 7:17:30 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Werewolf Therapeutics with a new price target

      Jefferies resumed coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $12.00 from $11.00 previously

      6/6/23 9:09:19 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    Financials

    Live finance-specific insights

    See more
    • Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

      Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) - Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS) or other typically severe IL-2-mediated toxicities - Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the

      11/3/23 7:00:00 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

      Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters representing an expansive body of data demonstrating the potential of Werewolf's PREDATOR™ platform and INDUKINE™ product candidates will also be presented.Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ET WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the d

      10/31/23 9:00:00 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

      SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

      11/14/24 4:04:06 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

      SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

      11/14/24 11:54:33 AM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

      SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

      11/13/24 4:30:24 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOWL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $487,188 worth of shares (536,426 units at $0.91) (SEC Form 4)

      4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

      5/14/25 6:08:19 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Bloom Steven H.

      4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

      5/2/25 5:38:59 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mpm Bioventures 2014, L.P. exercised 22,758 in-the-money shares at a strike of $0.09 and sold $2,061 worth of shares (1,963 units at $1.05) (SEC Form 4)

      4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

      4/30/25 4:17:02 PM ET
      $HOWL
      Biotechnology: Pharmaceutical Preparations
      Health Care